Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Virtual Booth

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

DIGITAL CONTENT

1 NEWS #PharmaBuzz

media
1 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

2DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 141206-42-0, (2r,3s,4r,5s)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol, N-(n-butyl)deoxygalactonojirimycin, Lucerastat [inn], Lucerastat [usan], Act-434964

Molecular Formula

C₁₀H₂₁NO₄

Molecular Weight

219.28 g/mol

InChI Key

UQRORFVVSGFNRO-XFWSIPNHSA-N

FDA UNII

GVS3YDM418

Lucerastat is under investigation in clinical trial NCT03425539 (Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease).

1 2D Structure

Lucerastat

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol

2.1.2 InChI

InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9+,10-/m1/s1

2.1.3 InChI Key

UQRORFVVSGFNRO-XFWSIPNHSA-N

2.1.4 Canonical SMILES

CCCCN1CC(C(C(C1CO)O)O)O

2.1.5 Isomeric SMILES

CCCCN1C[C@@H]([C@H]([C@H]([C@H]1CO)O)O)O

2.2 Other Identifiers

2.2.1 UNII

GVS3YDM418

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 1-butyl-2-(hydroxylmethyl)piperidine-3,4,5-triol

2. 1-deoxy-galactonojirimycin

3. 1-deoxygalacto-nojirimycin

4. 1-deoxygalactonojirimycin

5. At1001 Deoxyjirimycin

6. Galafold

7. Gr181413a

8. Migalastat

9. Migalastat Hcl

10. Migalastat Hydrochloride

11. N-butyldeoxygalacto-nojirimycin

12. N-butyldeoxygalactonojirimycin

13. Nb-dgj

2.3.2 Depositor-Supplied Synonyms

1. 141206-42-0

2. (2r,3s,4r,5s)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol

3. N-(n-butyl)deoxygalactonojirimycin

4. Lucerastat [inn]

5. Lucerastat [usan]

6. Act-434964

7. Gvs3ydm418

8. Chembl1086997

9. N-butyldeoxygalactonojirimycin

10. N-butyl-dgj

11. Unii-gvs3ydm418

12. Nbdgj

13. N-bu-dgj

14. Nb-dgj

15. Lucerastat [jan]

16. Lucerastat [usan:inn]

17. Lucerastat (jan/usan/inn)

18. N- Butyldeoxygalactonojirimycin

19. Schembl6821044

20. N-butyl-deoxy-galactonojirimycin

21. Cdp-923

22. Dtxsid60161601

23. N-n-butyl Deoxygalactonojirimycin

24. Ogt-923

25. Who 9539

26. Bdbm50312528

27. Mfcd00269939

28. Zinc13719785

29. N-butyl-d-galacto-1-deoxynojirimycin

30. Db14872

31. Ncgc00181326-01

32. Hy-106392

33. Cs-0025710

34. D11439

35. 1-butyl-2-hydroxymethyl-piperidine-3,4,5-triol

36. W-201205

37. Q27279309

38. (2r,3s,4r,5s)-1-butyl-2-(hydroxymethyl)-3,4,5-piperidinetriol

39. (2r,3s,4r,5s)-1-(but-1-yl)-2-(hydroxymethyl)piperidine-3,4,5-triol

40. 3,4,5-piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2r,3s,4r,5s)-

2.4 Create Date

2005-08-01

3 Chemical and Physical Properties

Molecular Formula	C₁₀H₂₁NO₄
Molecular Weight	219.28 g/mol
XLogP3	-0.6
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	4
Exact Mass	219.14705815 g/mol
Monoisotopic Mass	219.14705815 g/mol
Topological Polar Surface Area	84.2 Å²
Heavy Atom Count	15
Formal Charge	0
Complexity	190
Isotope Atom Count	0
Defined Atom Stereocenter Count	4
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Treatment of Fabry disease

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

ABOUT THIS PAGE

Find Lucerastat manufacturers, exporters & distributors on PharmaCompass

Lucerastat

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

DEVELOPMENTS

2 Drugs in Development

DIGITAL CONTENT

1 NEWS #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

2DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

What are you looking for?